Leonard S. Schleifer's Insider Trades & SAST Disclosures
Leonard S. Schleifer's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 14,879 Common Stock done at an average price of $1015.3 . Disclosure was reported to the exchange on June 11, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Leonard S. Schleifer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 1015.30 per share. | 11 Jun 2024 | 14,879 | 40,255 (0%) | 0% | 1015.3 | 15,106,649 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 1015.28 per share. | 11 Jun 2024 | 7,321 | 56,877 (0%) | 0% | 1015.3 | 7,432,865 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 1016.04 per share. | 11 Jun 2024 | 1,743 | 55,134 (0%) | 0% | 1016.0 | 1,770,958 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | 11 Jun 2024 | 1,000 | 1,000 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 1025.27 per share. | 11 Jun 2024 | 1,000 | 0 (0%) | 0% | 1025.3 | 1,025,270 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | 11 Jun 2024 | 1,000 | 14,775 | - | - | Class A Stock | ||
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 1016.62 per share. | 11 Jun 2024 | 270 | 39,985 (0%) | 0% | 1016.6 | 274,487 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 1015.02 per share. | 06 Jun 2024 | 787 | 64,198 (0%) | 0% | 1015.0 | 798,821 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 979.22 per share. | 17 May 2024 | 22,687 | 467,020 (0%) | 0% | 979.2 | 22,215,564 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 980.07 per share. | 17 May 2024 | 143 | 466,877 (0%) | 0% | 980.1 | 140,150 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 399.66 per share. | 13 May 2024 | 203,204 | 577,633 (0%) | 0% | 399.7 | 81,212,511 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 203,204 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 976.79 per share. | 13 May 2024 | 144,433 | 433,200 (0%) | 0% | 976.8 | 141,080,710 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 979.16 per share. | 13 May 2024 | 22,698 | 410,502 (0%) | 0% | 979.2 | 22,224,974 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 979.05 per share. | 13 May 2024 | 7,864 | 400,336 (0%) | 0% | 979.0 | 7,699,249 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 980.10 per share. | 13 May 2024 | 2,302 | 408,200 (0%) | 0% | 980.1 | 2,256,190 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 981.50 per share. | 13 May 2024 | 1,081 | 398,960 (0%) | 0% | 981.5 | 1,061,002 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 984.00 per share. | 13 May 2024 | 305 | 398,170 (0%) | 0% | 984 | 300,120 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 988.76 per share. | 13 May 2024 | 299 | 397,259 (0%) | 0% | 988.8 | 295,639 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 980.64 per share. | 13 May 2024 | 295 | 400,041 (0%) | 0% | 980.6 | 289,289 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 985.72 per share. | 13 May 2024 | 281 | 397,889 (0%) | 0% | 985.7 | 276,987 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 983.91 per share. | 13 May 2024 | 250 | 398,475 (0%) | 0% | 983.9 | 245,978 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 982.66 per share. | 13 May 2024 | 235 | 398,725 (0%) | 0% | 982.7 | 230,925 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 987.46 per share. | 13 May 2024 | 228 | 397,558 (0%) | 0% | 987.5 | 225,141 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, Bd. Co-Chair, President & CEO | Sale of securities on an exchange or to another person at price $ 986.57 per share. | 13 May 2024 | 103 | 397,786 (0%) | 0% | 986.6 | 101,617 | Common Stock |
| Regeneron Pharmaceuticals,... | S. Schleifer Leonard | Director, Bd. Co-Chair, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 25,155 | 0 | - | - | 2019 Performance Stock Units | |
| Regeneron Pharmaceuticals,... | Leonard Schleifer S. | Director, Bd. Co-Chair, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 25,155 | 387,270 (0%) | 0% | - | Common Stock | |
| Regeneron Pharmaceuticals,... | S. Schleifer Leonard | Director, Bd. Co-Chair, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 844.09 per share. | 11 Dec 2023 | 12,841 | 374,429 (0%) | 0% | 844.1 | 10,838,960 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2023 | 53,807 | 64,985 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2023 | 53,807 | 0 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 710.05 per share. | 05 Apr 2022 | 4,461 | 13,831 (0%) | 0% | 710.0 | 3,167,533 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 710.04 per share. | 05 Apr 2022 | 2,653 | 11,178 (0%) | 0% | 710.0 | 1,883,736 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 710.01 per share. | 31 Mar 2022 | 2,886 | 18,292 (0%) | 0% | 710.0 | 2,049,089 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2021 | 281,250 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 179.13 per share. | 19 Nov 2021 | 281,250 | 651,568 (0%) | 0% | 179.1 | 50,380,313 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2021 | 239,063 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 270.43 per share. | 19 Nov 2021 | 239,063 | 543,809 (0%) | 0% | 270.4 | 64,649,807 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 651.96 per share. | 19 Nov 2021 | 185,646 | 465,922 (0%) | 0% | 652.0 | 121,033,766 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 651.96 per share. | 19 Nov 2021 | 173,491 | 370,318 (0%) | 0% | 652.0 | 113,109,192 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 650.03 per share. | 18 Aug 2021 | 200,000 | 304,746 (0%) | 0% | 650.0 | 130,006,000 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 660.03 per share. | 18 Aug 2021 | 10,000 | 21,178 (0%) | 0% | 660.0 | 6,600,300 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 623.66 per share. | 16 Aug 2021 | 2,393 | 36,779 (0%) | 0% | 623.7 | 1,492,418 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 624.42 per share. | 16 Aug 2021 | 1,862 | 34,917 (0%) | 0% | 624.4 | 1,162,670 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 625.19 per share. | 16 Aug 2021 | 1,355 | 33,562 (0%) | 0% | 625.2 | 847,132 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 627.51 per share. | 16 Aug 2021 | 1,111 | 32,156 (0%) | 0% | 627.5 | 697,164 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 622.44 per share. | 16 Aug 2021 | 924 | 39,172 (0%) | 0% | 622.4 | 575,135 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 628.41 per share. | 16 Aug 2021 | 675 | 31,481 (0%) | 0% | 628.4 | 424,177 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 629.54 per share. | 16 Aug 2021 | 303 | 31,178 (0%) | 0% | 629.5 | 190,751 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 626.15 per share. | 16 Aug 2021 | 295 | 33,267 (0%) | 0% | 626.1 | 184,714 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 621.76 per share. | 16 Aug 2021 | 287 | 40,096 (0%) | 0% | 621.8 | 178,445 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 617.79 per share. | 16 Aug 2021 | 258 | 40,603 (0%) | 0% | 617.8 | 159,390 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 615.54 per share. | 16 Aug 2021 | 171 | 41,007 (0%) | 0% | 615.5 | 105,257 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 616.70 per share. | 16 Aug 2021 | 146 | 40,861 (0%) | 0% | 616.7 | 90,038 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 620.36 per share. | 16 Aug 2021 | 96 | 40,383 (0%) | 0% | 620.4 | 59,555 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 618.82 per share. | 16 Aug 2021 | 90 | 40,513 (0%) | 0% | 618.8 | 55,694 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 619.82 per share. | 16 Aug 2021 | 34 | 40,479 (0%) | 0% | 619.8 | 21,074 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.03 per share. | 06 Aug 2021 | 240,000 | 573,321 (0%) | 0% | 52.0 | 12,487,200 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 240,000 | 160,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 160,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.03 per share. | 06 Aug 2021 | 160,000 | 596,176 (0%) | 0% | 52.0 | 8,324,800 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 607.51 per share. | 06 Aug 2021 | 137,145 | 436,176 (0%) | 0% | 607.5 | 83,316,959 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 607.51 per share. | 06 Aug 2021 | 91,430 | 504,746 (0%) | 0% | 607.5 | 55,544,639 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2021 | 41,178 | 41,178 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Aug 2021 | 41,178 | 0 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.63 per share. | 11 May 2020 | 187,500 | 722,368 (0%) | 0% | 30.6 | 5,743,125 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2020 | 187,500 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.63 per share. | 11 May 2020 | 125,000 | 599,499 (0%) | 0% | 30.6 | 3,828,750 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2020 | 125,000 | 187,500 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 571.43 per share. | 11 May 2020 | 96,947 | 625,421 (0%) | 0% | 571.4 | 55,398,424 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 571.43 per share. | 11 May 2020 | 64,631 | 534,868 (0%) | 0% | 571.4 | 36,932,092 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 570.49 per share. | 11 May 2020 | 20,267 | 528,991 (0%) | 0% | 570.5 | 11,562,121 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 572.47 per share. | 11 May 2020 | 19,984 | 493,465 (0%) | 0% | 572.5 | 11,440,240 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 569.52 per share. | 11 May 2020 | 19,982 | 549,258 (0%) | 0% | 569.5 | 11,380,149 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 568.58 per share. | 11 May 2020 | 18,021 | 569,240 (0%) | 0% | 568.6 | 10,246,380 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 571.49 per share. | 11 May 2020 | 15,542 | 513,449 (0%) | 0% | 571.5 | 8,882,098 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 573.27 per share. | 11 May 2020 | 10,014 | 483,451 (0%) | 0% | 573.3 | 5,740,726 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 567.57 per share. | 11 May 2020 | 9,359 | 587,261 (0%) | 0% | 567.6 | 5,311,888 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 566.51 per share. | 11 May 2020 | 5,810 | 596,620 (0%) | 0% | 566.5 | 3,291,423 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 574.59 per share. | 11 May 2020 | 4,390 | 479,061 (0%) | 0% | 574.6 | 2,522,450 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 558.35 per share. | 11 May 2020 | 4,162 | 618,930 (0%) | 0% | 558.4 | 2,323,853 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 561.24 per share. | 11 May 2020 | 3,994 | 610,184 (0%) | 0% | 561.2 | 2,241,593 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 560.68 per share. | 11 May 2020 | 3,391 | 614,178 (0%) | 0% | 560.7 | 1,901,266 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 565.67 per share. | 11 May 2020 | 3,032 | 602,430 (0%) | 0% | 565.7 | 1,715,111 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 563.51 per share. | 11 May 2020 | 2,549 | 606,241 (0%) | 0% | 563.5 | 1,436,387 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 557.51 per share. | 11 May 2020 | 2,329 | 623,092 (0%) | 0% | 557.5 | 1,298,441 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 575.48 per share. | 11 May 2020 | 2,196 | 476,865 (0%) | 0% | 575.5 | 1,263,754 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 576.51 per share. | 11 May 2020 | 1,728 | 475,137 (0%) | 0% | 576.5 | 996,209 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 562.75 per share. | 11 May 2020 | 1,394 | 608,790 (0%) | 0% | 562.8 | 784,474 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 559.52 per share. | 11 May 2020 | 1,361 | 617,569 (0%) | 0% | 559.5 | 761,507 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 564.41 per share. | 11 May 2020 | 779 | 605,462 (0%) | 0% | 564.4 | 439,675 | Common Stock |
| Regeneron Pharmaceuticals,... | Leonard S. Schleifer | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 577.27 per share. | 11 May 2020 | 638 | 474,499 (0%) | 0% | 577.3 | 368,298 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges